Dr. Sarah H. Bartock is currently the National Science Director of Drug Monitoring and Toxicology at Quest Diagnostics where she leads a team of scientists and serves as liaison between business franchises, national operations, and R&D to ensure alignment and drive growth. Dr. Bartock earned her doctoral degree in Toxicology from the University of Maryland Baltimore. During and prior to her doctoral degree, Dr. Bartock held positions respectively at the Office of the Chief Medical Examiner in Baltimore, Maryland, and the Federal Bureau of Investigation Laboratory Division in Quantico, Virginia. Dr. Bartock received her board certification from the American Board of Forensic Toxicologists (F-ABFT) in 2018. She has worked with Quest Diagnostics for over 10 years, driving process improvements in oral fluid testing and prescription drug monitoring offerings with innovative analytical methods and new test offerings. Dr. Bartock has published nearly 20 peer-reviewed publications, first-authoring more than 10, with many focused on prenatal drug and alcohol detection and clinical and forensic toxicology. Working under Dr. Marilyn Huestis, Dr. Bartock collaborated with the Prenatal Alcohol in SIDS and Stillbirth Network (PASS), the Pediatric HIV/AIDS Cohort Study (PHACS), and the Infant Development, Environment, and Lifestyle (IDEAL) study to investigate infant toxicity prediction using biomarker presence in maternal and fetal matrices. Recently at Quest, she has focused on phosphatidylethanol (PEth), novel psychoactive substances (NPS), and per- and polyfluoroalkyl substances (PFAS).